推荐产品
![[去氨基-Cys1, D-Arg8]-加压素 乙酸盐 水合物 ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/215/222/82da3633-80ea-463d-8b55-e99fb8e442e0/640/82da3633-80ea-463d-8b55-e99fb8e442e0.png)
![[D-Gln4]-Desmopressin](/deepweb/assets/sigmaaldrich/product/images/428/484/f24f5afd-4405-4b8f-b2b8-c5c4699c065c/640/f24f5afd-4405-4b8f-b2b8-c5c4699c065c.jpg)
等級
pharmaceutical primary standard
API 家族
desmopressin
製造商／商標名
EDQM
應用
pharmaceutical (small molecule)
格式
neat
InChI
1S/C46H64N14O12S2.C2H4O2.3H2O/c47-35(62)15-14-29-40(67)58-32(22-36(48)63)43(70)59-33(45(72)60-18-5-9-34(60)44(71)56-28(8-4-17-52-46(50)51)39(66)53-23-37(49)64)24-74-73-19-16-38(65)54-30(21-26-10-12-27(61)13-11-26)41(68)57-31(42(69)55-29)20-25-6-2-1-3-7-25;1-2(3)4;;;/h1-3,6-7,10-13,28-34,61H,4-5,8-9,14-24H2,(H2,47,62)(H2,48,63)(H2,49,64)(H,53,66)(H,54,65)(H,55,69)(H,56,71)(H,57,68)(H,58,67)(H,59,70)(H4,50,51,52);1H3,(H,3,4);3*1H2
InChI 密鑰
YNKFCNRZZPFMEX-UHFFFAOYSA-N
一般說明
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
應用
Desmopressin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包裝
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他說明
PLEASE NOTE: TEMPORARILY UNAVAILABLE DUE TO RESTRICTED QUANTITY
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Pablo C Sandoval et al.
Journal of the American Society of Nephrology : JASN, 24(11), 1793-1805 (2013-09-14)
Vasopressin regulates water excretion, in part, by controlling the abundances of the water channel aquaporin-2 (AQP2) protein and regulatory proteins in the renal collecting duct. To determine whether vasopressin-induced alterations in protein abundance result from modulation of protein production, protein
Yutaka Oiso et al.
The Journal of clinical endocrinology and metabolism, 98(10), 3958-3967 (2013-07-26)
In recent years, there have been several improvements in the treatment of neurohypophyseal diabetes insipidus (DI). They include new formulations of the vasopressin analog, desmopressin; a better understanding of the effect of fluid intake on dosing; and more information about
Sara C M Stoof et al.
Thrombosis and haemostasis, 109(3), 440-449 (2013-01-26)
Desmopressin causes two- to six-fold increase of factor VIII (FVIII) in mild or moderate haemophilia A patients. However, responses are variable and little is known whether this is associated with F8 gene mutation. The study objective was to assess the
Philip Carsten Christophersen et al.
Pharmaceutical research, 31(9), 2420-2428 (2014-03-14)
To investigate the in vitro release and degradation of desmopressin from saturated triglyceride microparticles under both lipolytic and proteolytic conditions. The release of desmopressin from different solid lipid microparticles in the absence and presence of a microbial lipase and protease
Naoya Egami et al.
Laboratory investigation; a journal of technical methods and pathology, 93(9), 1001-1011 (2013-07-24)
The purpose of this study was to clarify the underlying mechanism of vertiginous attacks in Ménière's disease (MD) while obtaining insight into water homeostasis in the inner ear using a new animal model. We conducted both histopathological and functional assessment
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门